Investors Purchase Large Volume of Call Options on Moderna (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNAGet Free Report) was the recipient of some unusual options trading on Wednesday. Investors acquired 126,680 call options on the stock. This represents an increase of approximately 29% compared to the average daily volume of 98,118 call options.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lowered their price target on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday, March 21st. Leerink Partners dropped their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Royal Bank of Canada decreased their price objective on shares of Moderna from $32.00 to $28.00 and set a “sector perform” rating for the company in a report on Friday, May 2nd. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, April 17th. Finally, Evercore ISI lowered their price objective on shares of Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a report on Friday, May 2nd. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $53.95.

View Our Latest Report on Moderna

Moderna Trading Up 1.4 %

Shares of MRNA stock opened at $24.40 on Friday. Moderna has a 12-month low of $23.15 and a 12-month high of $170.47. The stock has a market capitalization of $9.43 billion, a P/E ratio of -2.63 and a beta of 1.99. The firm’s 50 day moving average is $29.01 and its 200 day moving average is $36.78.

Moderna (NASDAQ:MRNAGet Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million during the quarter, compared to analysts’ expectations of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. Moderna’s revenue for the quarter was down 35.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($3.07) earnings per share. As a group, equities analysts predict that Moderna will post -9.61 earnings per share for the current year.

Institutional Trading of Moderna

Several large investors have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB boosted its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares during the last quarter. Venturi Wealth Management LLC raised its holdings in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the period. Compass Planning Associates Inc bought a new stake in Moderna during the fourth quarter valued at about $37,000. Crowley Wealth Management Inc. purchased a new stake in Moderna in the fourth quarter worth about $41,000. Finally, Itau Unibanco Holding S.A. raised its stake in shares of Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock worth $42,000 after buying an additional 343 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Further Reading

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.